Latest Tax Incentives News

Noxopharm Limited has successfully completed the second dose cohort in its HERACLES Phase 1 trial for SOF-SKN™, confirming safety and tolerability and moving forward to a higher dose. This progress marks a key step in developing a novel autoimmune disease treatment.

Infini Resources has raised A$3 million through a flow-through share placement at a significant premium, fueling Phase 2 drilling at its Portland Creek Uranium Project in Canada. The capital raise underscores strong investor confidence ahead of a critical exploration push.

Mount Ridley Mines advances its rare earth exploration strategy with a detailed tenement review and key board appointments, while maintaining a solid cash position at the end of June 2025.

AUCyber reported a decline in Q4 FY25 customer receipts following a strategic exit from lower-margin contracts, while completing a $2.7 million capital raise that strengthens its cash position.

Tungsten Mining NL advances its Mt Mulgine project with a new gold extraction approach while reporting a maiden inferred resource at Hatches Creek, positioning itself strongly amid rising tungsten prices.

BirdDog Technology Limited reported a 6.9% increase in quarterly sales to A$4.3 million, driven by the successful launch of two next-generation broadcast products and a strong cash position ahead of a planned share buy-back.

Cardiex Limited reported a $3 million cash outflow in Q4 2025 but is banking on cost reductions and new product sales to improve its financial footing. The company also secured $6.5 million through a capital raise to bolster its runway.

Papyrus Australia has made significant strides in Q2 2025, launching its Rapid Prototyping and R&D Facility and successfully trialling new banana fibre-based products, while deepening academic partnerships.

Marquee Resources has progressed its Mt Clement antimony-gold project with Phase 1 drilling completed and assay results pending, alongside a $596,000 capital raise and a key executive appointment.

Cambium Bio has cleared key regulatory hurdles for its lead dry eye disease treatment, Elate Ocular, and strengthened its balance sheet with a $2.12 million placement to support upcoming Phase 3 trials.

Activeport Group Ltd reported a strong Q4 FY25 with significant revenue growth in software and Network as a Service segments, underpinned by new contracts with leading telecom providers and improved cash flow management.

ABx Group Limited reports promising rare earth exploration results in Tasmania, steady progress on its ALCORE fluorine recycling pilot plant, and advancing bauxite mining projects in Queensland and Tasmania, while managing funding challenges.